EUCTR2008-001339-37-IT进行中（未招募）不适用
Aprepitant in the prevention of cisplatin-induced delayed emesis: a double-blind randomized study - Aprepitant for cisplatin-induced delayed emesis
AZIENDA OSPEDALIERA S. MARIA DI TERNI0 个研究点目标入组 560 人开始时间: 2009年8月10日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 560
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- patients submitted for the first time to cisplatin chemotherapy administered in single dose
- •- patients over 18 years old that signed informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- patients submitted on days 2-4 after cisplatin to other antineoplastic agents except 5-fluorouracil, VP16, VM26, vincristine, vinblastine, vindesine, vinorelbine, gemcitabine
- •- patients already submitted to cisplatin
- •- patients with serious disease or with predisposition to emesis such as gastrointestinal obstruction, active peptic ulcer, hypercalemia and brain metastases
- •- patients with contraindications to dexamethasone administration (i.e. active peptic ulcer, previous blooding from peptic ulcer
- •- patients receiving concomitant radiotherapy
研究者
相似试验
尚未招募
3 期
Curcumin in the prevention of cisplatin-induced acute nephrotoxicityephrotoxicity.Other acute kidney failureN17.8IRCT20180722040556N8Esfahan University of Medical Sciences100
已完成
不适用
Feasibility study of the combination of cisplatin and docetaxel with concurrent thoracic radiotherapy for locally advanced resectable non-small cell lung cancer.ocally advanced resectable non-small-cell lung cancerJPRN-UMIN000008130Hamamatsu University School of Medicine3
已完成
3 期
The safety and efficacy of Aprepitant to the prevention of chemotherapy-induced nausea and vomitingIRCT20200819048455N1Iran University of Medical Sciences85
尚未招募
Unknown
A study to evaluate cisplatin induced hearing loss among patients of head and neck cancers receiving chemoradiation treatmentCTRI/2024/08/072465Sri Venkateshwara Institute of medical sciences
已完成
不适用
acetylcysteine as a Preventive Measure for Contrast Induced Nephropathy in Intensive Care Patients with Renal InsufficiencyRenal insufficiencyUrological and Genital DiseasesISRCTN43635237Academic Medical Centre (AMC) (Netherlands)246